Routine Management
PreclinicalSmall molecule
Routine Management is one of 24 small molecule programs targeting Gastrointestinal Disease. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
29 competitors in Gastrointestinal Disease
#DrugCompanyPhaseTrials
1Cipro
BayerApproved
Tofranil
SanofiApproved
Bayer Aspirin
BayerApproved
Elavil
AstraZenecaApproved
Lexapro
AbbVieApproved
Taxol
TevaApproved
Entereg
Merck & Co.Approved
IC-Green
CCHX Technologies Inc.
Approved
Reglan
IIstituto Clinico Humanitas
Approved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Routine Management. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSeton Healthcare Family